Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Targeting altered tumour metabolism is an emerging therapeutic strategy for cancer treatment. The metabolic reprogramming that accompanies the development of malignancy creates targetable differences between cancer cells and normal cells, which may be exploited for therapy. There is also emerging evidence regarding the role of stromal components, creating an intricate metabolic network consisting of cancer cells, cancer-associated fibroblasts, endothelial cells, immune cells, and cancer stem cells. This metabolic rewiring and crosstalk with the tumour microenvironment play a key role in cell proliferation, metastasis, and the development of treatment resistance. In this review, we will discuss therapeutic opportunities, which arise from dysregulated metabolism and metabolic crosstalk, highlighting strategies that may aid in the precision targeting of altered tumour metabolism with a focus on combinatorial therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088 · cited 1×
“Elevated PI3K signalling also activates extracellular FA uptake to further sustain intracellular FA levels for FA synthesis [37].”
BackgroundMetabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331 · cited 1×
“Ligation of PD-1 on activated T cells impair glycolysis or amino acid metabolism [137], while PD-1 blockade upregulates GLUT1 to restore glucose uptake, promoting glycolysis in effector T cells [94].”
BackgroundAMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300 · cited 1×
“Mechanistically, AMPK enhances sirtuin-1 (SIRT1) activity by increasing cellular NAD+ levels, leading to the deacetylation and modulation of the activity of downstream SIRT1 targets especially peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α) and the fork-head transcription factors FOXO1 and FO…”
BackgroundFunctional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
“…at single-cell resolution using advanced omics technologies, targeting multiple pathways with combination therapies, modulating the tumor microenvironment to reduce metabolic adaptability, and understanding the temporal dynamics of metabolic changes to develop phase-specific therapies [287].”
BackgroundHalford, S., Veal, G. J., Wedge, S. R., Payne, G. S., Bacon, C. M., Sloan, P., Dragoni, I., Heinzmann, K., Potter, S., Salisbury, B. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2263 · Cited by 276
Huang, J., Sun, W., Wang, Z., Lv, C., Zhang, T., Zhang, D., Dong, W., Shao, L., He, L., Ji, X., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02254-z · Cited by 198
“Studies have explored reprogramming of energy metabolism, and report that targeting glycolysis is a promising therapeutic strategy [25].”
BackgroundDeterminants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
“In this sense, a better understanding of the TME has provided multiple prognostic and diagnostic biomarkers in cancers of distinct origin (Bremnes et al., 2011).”
BackgroundInfluentialCellular landscaping of cisplatin resistance in cervical cancer
Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113345 · Cited by 93
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors
Zhao, Q., Wu, Z. E., Li, B., & Li, F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108256 · Cited by 57
Targeted Cancer Stem Cell Therapeutics: An Update
Fatima, N., Umar, M., Ambreen, S., Shaququzzaman, M., Alam, M. M., & Ali, R. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266275014240110071351 · Cited by 6
Metadata
- Authors
- Li, J., Eu, J. Q., Kong, L. R., Wang, L., Lim, Y. C., Goh, B. C., & Wong, A. L. A.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-10-20
- Volume
- 25
- Issue
- 20
- Pages
- 4831
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3094408967
- Cited by
- 159
- References
- 81
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.